GARY K. SCHOOLNIK, MD
Osteopathic Medicine at Pasteur Dr, Palo Alto, CA
License number
California G46217
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 723-4000
Professional information
Molecular Differences Between Species Of The M. Tuberculosis Complex
US Patent:
6686166, Feb 3, 2004
Filed:
Jun 27, 2001
Appl. No.:
09/894844
Inventors:
Marcel Behr - Montreal, CA
Peter Small - Stanford CA
Gary Schoolnik - Stanford CA
Michael A. Wilson - Stanford CA
Peter Small - Stanford CA
Gary Schoolnik - Stanford CA
Michael A. Wilson - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
G01N 3353
US Classification:
435 71, 435 4, 435 6, 4241901, 424 9, 4241841, 436501, 436517, 436518, 436536, 530300, 530350, 536 231
Abstract:
Specific genetic deletions are identified in mycobacteria isolates, including variations in the genome sequence between isolates, and numerous deletion present in BCG as compared to. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from or to attenuate the pathogenic bacteria.
Generation Of New Bcg Vaccine Strains Protecting Against The Establishment Of Latent Infection And Reactivation From The Latent Or Persistent State
US Patent:
7935354, May 3, 2011
Filed:
Nov 13, 2007
Appl. No.:
11/939144
Inventors:
Mario Alberto Flores-Valdez - Jalisco, MX
Gary K. Schoolnik - Palo Alto CA, US
Michel Klein - Zaandijk, NL
Jerald C. Sadoff - Washington DC, US
David Hone - Poolesville MD, US
Gary K. Schoolnik - Palo Alto CA, US
Michel Klein - Zaandijk, NL
Jerald C. Sadoff - Washington DC, US
David Hone - Poolesville MD, US
Assignee:
Aeras Global TB Vaccine Foundation - Rockville MD
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39/04, A61K 49/00, A61K 39/00
US Classification:
4242481, 536 231, 536 237, 424 91, 424 92, 4241841, 4242001
Abstract:
A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinant that overexpresses the transcription factor DosR, at a level sufficient to induce production of the dosR regulon genes or proteins. A host to whom the vaccine is administered mounts an immune response to the dosR regulon proteins and is thus protected from the establishment, persistence or reactivation of latent tuberculosis.
Molecular Differences Between Species Of The M. Tuberculosis Complex
US Patent:
6291190, Sep 18, 2001
Filed:
May 25, 1999
Appl. No.:
9/318191
Inventors:
Marcel Behr - Montreal, CA
Peter Small - Stanford CA
Gary Schoolnik - Stanford CA
Michael A. Wilson - Stanford CA
Peter Small - Stanford CA
Gary Schoolnik - Stanford CA
Michael A. Wilson - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
G01N 3353, A61K 3900, A61K 3902, C12Q 100, C12Q 168
US Classification:
435 71
Abstract:
Specific genetic deletions are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.
Polypeptide Pertussis Toxin Vaccine
US Patent:
5000952, Mar 19, 1991
Filed:
Aug 2, 1988
Appl. No.:
7/227372
Inventors:
Lawrence Steinman - Palo Alto CA
Jorge R. Oksenberg - Palo Alto CA
Gary K. Schoolnik - Palo Alto CA
Amrit K. Judd - Belmont CA
Jorge R. Oksenberg - Palo Alto CA
Gary K. Schoolnik - Palo Alto CA
Amrit K. Judd - Belmont CA
Assignee:
The Board of Trustees of the Leland Stanford, Jr. University - Stanford CA
International Classification:
A61K 3910
US Classification:
424 92
Abstract:
A novel method of defining oligopeptides is provided for determining useful immunodominant sequences for use as vaccines for pathogens. The method involves identifying sequences by particular selection procedures and using such sequences with antigen-presenting cells and T-cells to demonstrate activation of the common histocompatibility antigens DQ and DR in humans and their analogs in other animals. The oligopeptides may then be used individually or in combination to produce safe and effective vaccines, where genes may be prepared encoding the oligopeptides and used for expression of the oligopeptides or combinations of the oligopeptides or the gene transformed into the appropriate host, e. g. , B. pertussis, for use as a vaccine to the intact organism.
Broad Spectrum Vaccine Against Gonorrhea
US Patent:
4584195, Apr 22, 1986
Filed:
Jun 21, 1984
Appl. No.:
6/623178
Inventors:
Gary K. Schoolnik - Palo Alto CA
Jonathan Rothbard - San Francisco CA
Jonathan Rothbard - San Francisco CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
A61K 3902, A61K 3702, C07K 700
US Classification:
424 92
Abstract:
Vaccines comprising peptide sequences corresponding to immunorecessive determinants in gonorrhea pilus protein are disclosed. The vaccines are effective in protecting human subjects against infection by a wide range of gonorrhea strains by raising antibodies which interfere with the colonization of the epithelium by the infecting bacteria.
Molecular Differences Between Species Of The Complex
US Patent:
7700118, Apr 20, 2010
Filed:
Mar 14, 2008
Appl. No.:
12/049063
Inventors:
Marcel Behr - Montreal, CA
Peter Small - Seattle WA, US
Gary Schoolnik - Stanford CA, US
Michael A. Wilson - Austin TX, US
Peter Small - Seattle WA, US
Gary Schoolnik - Stanford CA, US
Michael A. Wilson - Austin TX, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39/04, A61K 39/205, A61K 39/00
US Classification:
4242481, 424 91, 424 92, 424 932, 4241851, 4242341
Abstract:
Specific genetic deletion are identified in mycobacteria isolates, including variations in the genome sequence between isolates, and numerous deletion present in BCG as compared to. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from or to attenuate the pathogenic bacteria.
Molecular Differences Between Species Of The M. Tuberculosis Complex
US Patent:
2011020, Aug 25, 2011
Filed:
Apr 2, 2010
Appl. No.:
12/753330
Inventors:
MARCEL BEHR - MONTREAL, CA
PETER SMALL - SEATTLE WA, US
GARY SCHOOLNIK - STANFORD CA, US
MICHAEL A. WILSON - AUSTIN TX, US
PETER SMALL - SEATTLE WA, US
GARY SCHOOLNIK - STANFORD CA, US
MICHAEL A. WILSON - AUSTIN TX, US
International Classification:
A61K 39/04, C12N 1/21, A61P 37/04, A61P 31/06
US Classification:
4241921, 4242481, 4242001, 4352523
Abstract:
Specific genetic deletion are identified in mycobacteria isolates, including variations in the genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb. isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be reintroduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from or to attenuate the pathogenic bacteria.
Molecular Differences Between Species Of The Complex
US Patent:
7364740, Apr 29, 2008
Filed:
Jun 1, 2005
Appl. No.:
11/143401
Inventors:
Marcel Behr - Montreal, CA
Peter Small - Seattle WA, US
Gary Schoolnik - Stanford CA, US
Michael A. Wilson - Bethesda MD, US
Peter Small - Seattle WA, US
Gary Schoolnik - Stanford CA, US
Michael A. Wilson - Bethesda MD, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 48/00, A61K 39/02, A61K 39/04, C12N 1/21, C12N 15/63, C07H 21/04
US Classification:
4241851, 424 931, 424 932, 424 934, 4241841, 4241901, 4241921, 4241931, 42419711, 4242341, 4242481, 4353201, 4352523, 4352531, 514 2
Abstract:
Specific genetic deletion are identified in mycobacteria isolates, including variations in the genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from or to attenuate the pathogenic bacteria.
Diagnostic Peptides Of Human Papilloma Virus
US Patent:
4777239, Oct 11, 1988
Filed:
Jul 10, 1986
Appl. No.:
6/884184
Inventors:
Gary K. Schoolnik - Palo Alto CA
Joel M. Palefsky - Redwood City CA
Joel M. Palefsky - Redwood City CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
C07K 706, C07K 708, C07K 1514
US Classification:
530326
Abstract:
A series of seventeen synthetic peptides which are capable of raising antibodies specific for certain desired human papilloma virus (HPV) are useful in diagnosis and therapy of conditions associated with HPV infection.
Use Of Defensins Against Tuberculosis
US Patent:
2011005, Mar 3, 2011
Filed:
Nov 2, 2010
Appl. No.:
12/917555
Inventors:
HANS-HENRIK KRISTENSEN HOGENHAUG - SOLLEROD, DK
GARY K. SCHOOLNIK - PALO ALTO CA, US
SIDHARTH CHOPRA - MENLO PARK CA, US
DOROTEA RAVENTOS SEGURA - HUMLEBAEK, DK
GARY K. SCHOOLNIK - PALO ALTO CA, US
SIDHARTH CHOPRA - MENLO PARK CA, US
DOROTEA RAVENTOS SEGURA - HUMLEBAEK, DK
Assignee:
NOVOZYMES ADENIUM BIOTECH A/S - BAGSVAERD
International Classification:
A61K 38/16, A61P 31/04, A61P 31/06
US Classification:
514 24
Abstract:
The present invention relates to a method for killing or inhibiting cells of , in particular , with certain defensins.